Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016', provides in depth analysis on Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted pipeline therapeutics. The report provides comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - The report reviews Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics and enlists all their major and minor projects - The report assesses Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) Overview 7 Therapeutics Development 8 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Stage of Development 8 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Therapy Area 9 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Indication 10 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Products under Development by Companies 13 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 18 Assessment by Molecule Type 19 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Companies Involved in Therapeutics Development 20 BioCrea GmbH 20 Bristol-Myers Squibb Company 21 Cerecor Inc. 22 Johnson & Johnson 23 Luc Therapeutics, Inc. 24 NeurOp, Inc 25 Novartis AG 26 UCB S.A. 27 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Drug Profiles 28 CERC-301 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 EVT-100 Series - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 EVT-103 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 NP-10679 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 NP-11948 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 radiprodil - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated With Schizophrenia - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecules to Antagonize NR2B for Depression - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecules to Antagonize NR2B for Neuropathic Pain - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Dormant Projects 42 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Discontinued Products 43 Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Featured News & Press Releases 44 Jan 19, 2016: Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model 44 Sep 03, 2015: Cerecor Initiates Phase 2 Study for CERC-301, an Antidepressant Product Candidate with Potential for Rapid Onset of Effect 44 Mar 20, 2015: Cerecor Provides Update on CERC-301 Development in Major Depressive Disorder 44 Oct 03, 2014: Cerecor to Present at 13th Annual BIO Investor Forum 45 Oct 02, 2014: NeurOp Receives Milestone Payment as Bristol-Myers Squibb Nominates NMDA Receptor Compound as Drug Development Candidate 45 Dec 02, 2013: MedAvante Central Ratings Selected For Cerecor Investigational MDD Study 46 Nov 25, 2013: Cerecor Receives Fast Track Designation for CERC-301 for the Treatment of Major Depressive Disorder 46 Nov 08, 2013: Cerecor Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate 47 Jun 28, 2010: Forest And Gedeon Richter Announce Phase II Study Results Of Radiprodil For Treatment Of Diabetic Peripheral Neuropathic Pain 48 Mar 11, 2010: Evotec Completes Clinical Part Of First Phase I Study Of EVT 103 48 Sep 08, 2009: Evotec Starts Phase I With EVT 103, An NR2B-Selective NMDA Receptor Antagonist 49 Nov 29, 2005: Gedeon Richter And Forest Laboratories Expand Relationship With Two New Collaborations For CNS Compounds 49 Mar 24, 2004: Evotec Neurosciences License NMDA Receptor NR2B Subunit Selective Antagonists From Roche 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by BioCrea GmbH, H1 2016 20 Pipeline by Bristol-Myers Squibb Company, H1 2016 21 Pipeline by Cerecor Inc., H1 2016 22 Pipeline by Johnson & Johnson, H1 2016 23 Pipeline by Luc Therapeutics, Inc., H1 2016 24 Pipeline by NeurOp, Inc, H1 2016 25 Pipeline by Novartis AG, H1 2016 26 Pipeline by UCB S.A., H1 2016 27 Dormant Projects, H1 2016 42 Discontinued Products, H1 2016 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
